Format

Send to

Choose Destination
J Endocrinol Invest. 2016 Aug;39(8):923-31. doi: 10.1007/s40618-016-0460-6. Epub 2016 Mar 29.

Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive.

Author information

1
Department of General Surgery and Medical Surgical Specialties, Gynecological Clinic, Policlinico Universitario, Via S.Sofia 78, 95124, Catania, Italy. scaruso@unict.it.
2
Research Group for Sexology, Catania, Italy. scaruso@unict.it.
3
Department of General Surgery and Medical Surgical Specialties, Gynecological Clinic, Policlinico Universitario, Via S.Sofia 78, 95124, Catania, Italy.
4
Research Group for Sexology, Catania, Italy.

Abstract

PURPOSE:

To evaluate the effects of a continuous regimen combined oral contraceptive (COC) containing 2 mg dienogest and 30 µg ethinyl estradiol (DNG/EE) compared to a 21/7 regimen on the quality of life (QoL) and sexual function in women affected by endometriosis-associated pelvic pain.

METHODS:

Sixty-three women constituted the Study group treated with DNG/EE COC continuous regimen; 33 women were given DNG/EE COC in a 21/7 regimen. To define the endometriosis-associated pelvic pain, the Visual Analogic Scale was used. The Short Form-36, Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess QoL, sexual function and sexual distress, respectively. The study included two follow-ups.

RESULTS:

At 3 and 6 months of treatment there was an improvement in pain of the Study group (p < 0.001). The Control group underwent pain improvement at the second follow-up (p < 0.05). At the first and the second follow-ups, the Study group reported QoL improvements in all categories (p < 0.001). The Control group reported QoL improvements in all categories at the second follow-up (p < 0.05). At the first and the second follow-ups of the Study group, the FSFI total score had risen (p < 0.001), and the FSDS score had dropped (p < 0.001). An improvement of the FSFI score and a reduction of the FSDS score of the Control group was observed at the second follow-up (p < 0.001), but not at the first follow-up (p = NS).

CONCLUSIONS:

Women on DNG/EE COC continuous regimen reported a reduction of endometriosis-associated pelvic pain and there was an improvement of their sexual activity and their QoL that was better than the DNG/EE 21/7 conventional regimen.

KEYWORDS:

Chronic pelvic pain; Continuous regimen COC; Dienogest; Endometriosis; Ethinyl estradiol; Quality of life; Sexual life

PMID:
27023105
DOI:
10.1007/s40618-016-0460-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center